An interventional study of Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap in Failed Carpal Tunnel Syndrome Surgery, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Sohag University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Carpal Tunnel Syndrome with a site in Egypt — 20 open to participants now, 22 under way, 1 of them phase 3. Carpal Tunnel Syndrome · Egypt.
Among the 64 studies in Carpal Tunnel Syndrome with a site in Egypt, this one is the 53rd largest by planned enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2024, is one of 44 with no phase, reaches primary completion later than 13 of the 21 other live ones, and was the 42nd registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →20 of the 64 studies in Carpal Tunnel Syndrome with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–40
Tanta University · Sites in Egypt
Ages 18–70
Kafrelsheikh University · Sites in Egypt
Ages 18+
Osama Ahmed Elshafei · Sites in Egypt
Ages 18–65
Cairo University · Sites in Egypt
Ages 40–60 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 2 · Phase 4 3
First in 2016; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 60 across the 53 interventional studies, 50 across the 11 observational. Of the 31 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 64 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 3 studies filed under Carpal Tunnel Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Carpal Tunnel Syndrome with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07700316Delta University for Science and TechnologyCompare the Effect of Radiofrequency (TECAR) and Ultrasound on Sensation, Hand Dexterity, and Quality of Life in Patients With Carpal Tunnel Syndrome. | 2026-12-31 |
| NCT07539480Middle East UniversityPain Neuroscience Education Versus Kinesio Tape on Functional Outcomes in Patients With Carpal Tunnel Syndrome | 2027-09-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 64 studies in Carpal Tunnel Syndrome with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Carpal tunnel syndrome (CTS) is the most common compressive neuropathy in the general population. Surgical treatment by open or endoscopic carpal tunnel release (CTR) is the first choice of treatment and has clinical success rates of 75% to 90%.The rate of recurrence after primary median nerve release is 3-19% [1,2]. Between 0.3% and 12% of cases require surgical revision [2,3]. The risk factors for surgical revision for secondary release are male gender, staged or simultaneous bilateral carpal tunnel release, endoscopic release, smoking and rheumatoid arthritis.
Treatment failures after primary CTR are classified as persistent CTS, recurrent CTS, or new symptoms. Recurrent symptoms are uncommon and are defined by a symptom-free interval after surgery. Persistent symptoms are relatively common, particularly in elderly patients and in patients with concurrent nerve compression or medical conditions that affect nerve function, such as diabetes. Persistent or recurrent CTS principally results from incomplete release of the transverse carpal ligament but may be accompanied by perineural scarring, leading to compression or tethering of the median nerve.
New symptoms may be caused by iatrogenic nerve injury. Surgical treatment of recurrent or persistent CTS after primary CTR usually involves open revision CTR, extended proximally into unscarred tissue, and has also included internal or external neurolysis. Unsatisfactory results following revision CTR are common.
A second compression site, or double-crush syndrome, may clinically present as RCTS or PCTS . Thorough preoperative clinical examination may uncover signs of a second compression site, which can then be confirmed on electroneuromyography (ENMG) of the entire arm.
To improve outcomes of revision CTR, recent studies have emphasized the importance of median nerve coverage by well-vascularized soft tissue to enhance nerve healing, to prevent tethering in surrounding scar tissue, and to optimize nerve gliding in the carpal tunnel. Several local flaps (hypothenar fat pad flap, tenosynovial flap), regional flaps (posterior interosseous artery flap, reverse radial artery fascial flap, flexor digitorum superficialis flap), and free flap techniques have been described, but consensus for specific flap has not been reached. Following potential iatrogenic median nerve injury and reexploration for a painful neuroma incontinuity, flap coverage may also be beneficial.
In 1988, Becker and Gilbert introduced a Fasciocutaneous pedicled flap based on a consistent dorsal perforator of the ulnar artery (absent in 1 % of population) named the dorsal ulnar artery (DUA) flap or simply the Becker flap. The authors described open revision CTR with nerve coverage by a DUA flap in 3 patients with recurrent CTS and reported good results as well as a quick and easy-to-perform dissection with low donor site morbidity and preservation of the radial andulnar artery. Since this introduction, additional studies describing fasciocutaneous DUA flaps have mostly focused on its use for reconstruction of hand or wrist wounds. Despite the original described benefits, additional studies of DUA flaps for the treatment of recurrent or persistent CTS have remained limited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap The previous incision is reopened and extended, Neurolysis begins proximally preserving the palmar cutaneous branch. The subcutaneous tissue is exposed, leaving part of the superficial venous plexus with the adipofascial flap. Flap elevation is begun by incising the subcutaneous tissue through the deep fascia along the radial border of FCU and ECU . When the flap reaches a suitable length (10-12 cm from the wrist), it is cut proximally and along the ulnar side. The flap is dissected proximally to distally in continuity with the underlying fascia . When the dissected flap is (2-5) cm proximal to the wrist. Ulnar retraction of the flexor carpi ulnaris permits identification of the perforator. the pivot point of the flap is localized (2-5) cm proximal to the pisiform. The adipofascial flap is turned 180 degrees and anchored with a few absorbable stitches around the median nerve.
Pain visual analogue scale (VAS)
The visual analog scale for pain is a straight line with one end meaning no pain and the other end .meaning the worst pain imaginable. A patient marks a point on the line that matches the amount of pain he or she feels.Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain".the position of the respondent's cross is generally assigned a score between 0 and 100. If documented in paper form, the scores can then be simply transferred to a 100-value scale using a millimeter tape measure
Time frame: 1 year
Two point discrimination test
one of the most commonly used neurosensory tests to assess mechanoperception in the clinical settings. While there have been numerous studies of functional sensibility of the hand using TPD test.
Time frame: 1 year
Tinel sign
a tingling or "pins and needles" feeling you get when your healthcare provider taps your skin over a nerve. Tinel's sign may be an indicator that you have nerve compression or damage where they're tapping
Time frame: 1 year
Plan to share: Undecided
Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.
Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 21 months is above that.
Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.